Financial Performance - The company's operating revenue for Q3 2024 was ¥233,925,588.87, a decrease of 15.52% compared to ¥273,958,024.48 in the same period last year[4] - Net profit attributable to shareholders for Q3 2024 was ¥11,361,158.38, down 70.98% from ¥14,423,083.20 year-on-year[4] - The net profit after deducting non-recurring gains and losses for Q3 2024 was ¥9,488,994.37, a decrease of 64.19% compared to ¥2,675,325.40 in the previous year[4] - The basic earnings per share for Q3 2024 was ¥0.02, down 75.00% from ¥0.03 in the same period last year[4] - Total operating revenue for the first three quarters of 2024 was CNY 893,525,764.69, a decrease of 7.93% compared to CNY 970,470,739.58 in the same period of 2023[15] - Net profit for the first three quarters of 2024 was CNY 80,327,259.54, compared to CNY 93,614,632.03 in 2023, indicating a decline of 14.14%[15] - The total comprehensive income for Q3 2024 was ¥80,327,259.54, down from ¥93,614,632.03 in Q3 2023, reflecting a decline of 14.1%[16] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥136,053,785.23, a decline of 62.16% compared to ¥359,515,911.53 in the same period last year[4] - Cash inflows from operating activities totaled ¥1,197,449,684.17 in the first three quarters of 2024, up from ¥1,150,676,072.65 in the same period of 2023, representing a growth of 4.1%[17] - Cash outflows from operating activities increased to ¥1,061,395,898.94 in Q3 2024, compared to ¥791,160,161.12 in Q3 2023, marking a significant rise of 34.2%[17] - The net cash flow from operating activities for the first three quarters of 2024 was ¥136,053,785.23, down 62.2% from ¥359,515,911.53 in the same period of 2023[17] - Cash and cash equivalents at the end of Q3 2024 were ¥135,999,306.73, a decrease from ¥225,853,031.40 at the end of Q3 2023, reflecting a decline of 39.7%[18] - The company reported a significant decrease in cash flow due to increased raw material prices and timely payments to suppliers[7] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,402,750,926.24, down 8.59% from ¥2,628,413,544.42 at the end of the previous year[5] - Total liabilities decreased to CNY 814,559,959.25 in 2024 from CNY 1,120,549,836.97 in 2023, a reduction of 27.24%[14] - The total equity attributable to shareholders increased to CNY 1,567,091,851.02 in 2024 from CNY 1,496,127,641.31 in 2023, an increase of 4.76%[14] - The company received government subsidies amounting to ¥14,914,371.03 year-to-date, which contributed to the financial results[6] Shareholder Information - As of September 30, 2024, the total number of ordinary shareholders is 65,354, with the largest shareholder, Jinchang Investment Co., Ltd., holding 71,508,968 shares, representing 14.61% of the total share capital[8] - The company has a total of 2,724,500 shares directly held by its controlling shareholder, Shennong Technology Group, which represents 0.56% of the total share capital[11] - The company has not reported any changes in the status of pledged, marked, or frozen shares for the top shareholders[9] - The company’s major shareholders have not disclosed any known relationships or agreements that would classify them as acting in concert under the relevant regulations[9] Inventory and Receivables - Accounts receivable decreased to ¥381,395,050.41 from ¥488,346,960.66, reflecting a reduction of about 22%[12] - Inventory increased significantly to ¥761,541,437.18 from ¥569,530,008.23, marking an increase of approximately 33.7%[12] - The company reported a significant increase in other receivables, rising to ¥72,393,238.37 from ¥8,031,217.93, indicating a growth of over 800%[12] Research and Development - Research and development expenses increased to CNY 27,910,261.53 in 2024 from CNY 24,426,723.77 in 2023, representing a growth of 10.16%[15] - The company plans to continue investing in R&D to enhance product offerings and market competitiveness despite the current financial challenges[15] Future Plans - The company plans to increase its shareholding through market transactions, with a planned investment between ¥50 million and ¥100 million over the next 12 months, starting from August 26, 2024[11]

证券代码：600771 证券简称：广誉远 编号：临 2024-039 4、公司全体监事承诺 2024 年第三季度报告所载资料不存在任何虚假记载、误导性 陈述或重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 特此公告。 广誉远中药股份有限公司 第八届监事会第十次会议决议公告 特别提示 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司第八届监事会第十次会议于 2024 年 10 月 15 日以电话、 邮件及其他网络通讯方式发出通知，于 2024 年 10 月 25 日以通讯方式召开。会议应出 席监事 3 名，亲自出席监事 3 名，符合《公司法》及《公司章程》的有关规定。会议由 监事会主席张华中主持，经认真审议，以"同意 3 票，反对 0 票，弃权 0 票"的表决结 果全票通过了《公司 2024 年第三季度报告》。 监事会对《公司 2024 年第三季度报告》进行了审慎审核，认为： 1、公司 2024 年第三季度报告的编制和审议程序符合法律法规、公司章程和公司内 部管理制度的规定。 2、公司 2 ...

证券代码：600771 证券简称：广誉远 编号：临 2024-038 广誉远中药股份有限公司（以下简称"公司"）第八届董事会第十二次会议于 2024 年 10 月 15 日以电话、邮件及其他网络通讯方式向全体董事发出通知，于 2024 年 10 月 25 日以通讯方式召开。会议应出席董事 6 名，实际出席董事 6 名，符合《公司法》及 《公司章程》的有关规定。会议由董事长李晓军主持，经大会认真审议，通过了以下议 案： 一、审议通过《公司 2024 年第三季度报告》 《公司 2024 年第三季度报告》已经董事会审计委员会审议通过，同意将该报告提 交公司董事会审议。 表决情况：同意 6 票，反对 0 票，弃权 0 票。 具体内容详见公司同日在上海证券交易所网站披露的《公司2024年第三季度报告》。 二、审议通过《广誉远中药股份有限公司舆情管理制度（试行）》 广誉远中药股份有限公司 第八届董事会第十二次会议决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为了完善公司内部管理制度体系，提高公司应对各类舆情的规范管理 ...

Group 1: Product Overview - The company's core products, Gui Ling Ji and Ding Kun Dan, have significant therapeutic effects and are positioned for both health maintenance and treatment [4][5][6]. - Gui Ling Ji is suitable for a wide range of chronic conditions, including over a hundred diseases such as rheumatism, gout, and osteoporosis, enhancing memory and restoring bodily functions [3][4]. - Ding Kun Dan targets women's health, focusing on regulating menstrual cycles and improving overall vitality, with over 5,000 cases collected for clinical research [4][5]. Group 2: Market Strategy - The company is actively collecting treatment cases and conducting targeted marketing strategies to better match consumer needs [4][5]. - Innovative marketing strategies include cultural exploration, digital transformation, and resource collaboration to enhance brand influence and market competitiveness [4][5]. - The company emphasizes brand building and cultural heritage to engage younger consumers and rejuvenate the brand's image [5][6]. Group 3: Financial Performance - The company reported a net profit of over 150 million in other income for the first half of 2024, compared to over 190 million for the entire previous year [8][9]. - The inventory value as of mid-2024 was 694 million, accounting for 44.6% of net assets, reflecting a 21.82% increase from the previous year [14]. - Sales expenses have decreased from 70.11% in 2022 to 44.7% in the first half of 2024, indicating improved cost management [14]. Group 4: Regulatory and Product Development - The company is exploring the possibility of converting Gui Ling Ji from a prescription drug to an OTC product, which requires full disclosure of the formula and compliance with national policies [9][10]. - The unique production techniques of An Gong Niu Huang Wan have been recognized as a national intangible cultural heritage, enhancing its market position [6][7]. - The company is cautious about disclosing proprietary formulas due to their classified status, which impacts its ability to market certain products [10][11]. Group 5: Future Plans and Challenges - The company is focusing on the revitalization of Gui Jiu (turtle wine) and has established a dedicated wine production and marketing company to enhance operational efficiency [8][9]. - There are plans to expand product offerings and explore international markets, although current regulations limit overseas sales [13][14]. - The company aims to improve employee training and attract external talent to enhance operational efficiency and market communication [12][13].

证券代码：600771 证券简称：广誉远 编号：临 2024-036 广誉远中药股份有限公司 关于控股股东首次增持公司股份暨后续增持计划的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司于 2024 年 8 月 26 日收到控股股东神农科技集团《关于增持广誉远股票的告知 函》，现将有关情况公告如下： 1 首次增持情况：2024 年 8 月 26 日，广誉远中药股份有限公司（以下简称"公司" "广誉远"）控股股东神农科技集团有限公司（以下简称"神农科技集团"）通 过集中竞价方式增持了公司股票 389,100 股，占公司总股本的 0.079%，本次增 持成交总额 6,427,360 元（不含手续费）。 增持计划基本情况：基于对公司未来发展的信心和长期投资价值的认可，为提 升投资者信心，切实维护中小股东利益和市场稳定，神农科技集团拟实施广誉 远股票增持计划，以更好地支持广誉远未来持续、稳定、健康的发展。神农科 技集团计划自 2024 年 8 月 26 日起 12 个月内，以集中竞价、大宗交易等符合 ...

证券代码：600771 证券简称：广誉远 编号：临 2024-035 广誉远中药股份有限公司 1 会议召开时间：2024 年 08 月 30 日（星期五）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、说明会类型 广誉远中药股份有限公司（以下简称"公司"）已于 2024 年 8 月 23 日披露了《2024 年半年度报告》及《2024 年半年度报告摘要》。为便于广大投资者更加全面深入地了解 公司经营业绩、发展战略及财务状况等情况，公司定于 2024 年 08 月 30 日（星期五） 15:00-16:00 在"价值在线"（www.ir-online.cn）举办广誉远中药股份有限公司 2024 关于召开 2024 年半年度业绩说明会的预告公告 特别提示 会议召开方式：网络文字互动方式 会议问题征集：投资者可于 2024 年 08 月 28 日 15：00 前通过访问网址 https://eseb.cn/1haVHfXY33a ...

养生精品中药 始于1541 2023 环境 社会及治理报告 Environmental Social and Governance Report | Produce of I Ad I Ad I January of Art I Jan Landers | | --- | | 1.2 公司治理 加强完善 | | 1.3 利益相关方沟通 | | 1.4 实质性议题识别 | | 1.5 实质性议题矩阵 | | 1.6 廉洁合规 构筑底线 | | 1.7 守护网络 保护隐私 | 2 3 关于本报告 【报告说明 《广誉远中药股份有限公司 2023 年度环境、社会及治理报告》（以下简称"ESG 报告""本报告"）是广誉远中药股份有限 公司第一份 ESG 报告，旨在向各利益相关方真实、客观地展示公司在环境、社会和治理方面所采取的行动和达到的成效，系 统地回应利益相关方的期望和要求，促进公司更好发展的同时，积极履行社会责任。 [ 时间范围 ( 发布周期 本报告为年度报告。 [ 报告称谓 为便于表述和阅读，报告中"广誉远中药股份有限公司"也以"广誉远""公司"或"我们"表示。 数据说明 本报告使用数据来源包括公司实际运行的原 ...

证券代码：600771 证券简称：广誉远 编号：临 2024-034 广誉远中药股份有限公司 3、在提出本意见之前，监事会未发现参与半年报编制和审议的人员有违反保密规 定的行为。 4、公司全体监事承诺 2024 年半年度报告所载资料不存在任何虚假记载、误导性陈 述或重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 1 特此公告。 第八届监事会第九次会议决议公告 特别提示 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司第八届监事会第九次会议于 2024 年 8 月 12 日以电话、邮 件及其他网络通讯方式发出通知，于 2024 年 8 月 22 日以现场方式在山西省晋中市太谷 区广誉远路 1 号山西广誉远国药有限公司会议室召开。会议应出席监事 3 名，亲自出席 监事 3 名，符合《公司法》及《公司章程》的有关规定。会议由监事会主席张华中主持， 经认真审议，以"同意 3 票，反对 0 票，弃权 0 票"的表决结果全票通过了《公司 2024 年半年度报告及摘要》。 监事会对《广誉远中药股份有限 ...

广誉远中药股份有限公司（以下简称"公司"）第八届董事会第十一次会议于 2024 年 8 月 12 日以电话、邮件及其他网络通讯方式向全体董事发出通知，于 2024 年 8 月 22 日在山西省晋中市太谷区广誉远路 1 号山西广誉远国药有限公司会议室以现场结合通 讯方式召开。会议应出席董事 7 名，实际出席董事 7 名，其中董事季占璐、刘兆维及独 立董事赵选民通过通讯方式参会。公司全体监事及高管列席了会议，符合《公司法》及 《公司章程》的有关规定。会议由董事长李晓军主持，经大会认真审议，通过了以下议 案： 一、审议通过《公司 2023 年度环境、社会及治理（ESG）报告》 为切实履行好国有企业社会责任，提高公司核心竞争力，有效推进上市公司可持续 发展目标，公司编制了《广誉远中药股份有限公司 2023 年度环境、社会及治理（ESG） 报告》。 表决情况：同意 7 票，反对 0 票，弃权 0 票。 证券代码：600771 证券简称：广誉远 编号：临 2024-033 广誉远中药股份有限公司 第八届董事会第十一次会议决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏， ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the first half of 2024, representing a year-on-year growth of 15%[8]. - The company's operating revenue for the first half of 2024 was ¥659.6 million, a decrease of 4.90% compared to ¥693.6 million in the same period last year[13]. - Net profit attributable to shareholders was ¥59.6 million, an increase of 13.75% from ¥52.4 million in the previous year[13]. - The net cash flow from operating activities decreased by 41.74% to ¥162.3 million, primarily due to increased raw material prices and timely payments to suppliers[16]. - Basic earnings per share rose to ¥0.12, reflecting a 9.09% increase from ¥0.11 in the same period last year[14]. - The company's total assets decreased by 9.20% to ¥2.39 billion from ¥2.63 billion at the end of the previous year[13]. - The company's total operating revenue for the first half of 2024 was CNY 659.60 million, a decrease of 4.90% compared to CNY 693.56 million in the same period last year[54]. - Operating costs decreased by 12.21% to ¥164.34 million from ¥187.19 million year-on-year[54]. - The company reported a net loss reduction from CNY 608,674,316.23 to CNY 549,071,264.90, indicating an improvement in financial performance[123]. Market Expansion and Strategy - User data indicates a growth in active customers, with the number reaching 2 million, an increase of 25% compared to the same period last year[8]. - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 20% based on current market trends and product demand[8]. - New product launches are expected to contribute an additional 300 million CNY in revenue, with a focus on herbal supplements and traditional medicine innovations[8]. - The company is expanding its market presence, targeting an increase in distribution channels by 30% across major cities in China by the end of 2024[8]. - A strategic acquisition of a local herbal product manufacturer is in progress, which is anticipated to enhance the company's product portfolio and market share[8]. - The company is focusing on the development of new products and technologies, particularly in the area of traditional Chinese medicine formulations[28]. - The company is actively integrating online e-commerce, internet medical services, and traditional Chinese medicine culture to create a comprehensive business ecosystem[47]. Research and Development - The company is investing 50 million CNY in research and development for new technologies in traditional medicine, aiming to improve product efficacy and safety[8]. - Research and development expenses increased by 11.99% to ¥17.94 million compared to ¥16.02 million in the previous year[54]. - The company has 22 ongoing R&D projects focused on enhancing product academic promotion and clinical research data[50]. - The company is actively pursuing the development of classic formulas and the restoration of dormant varieties to enhance long-term competitiveness[50]. Regulatory and Compliance Issues - The company has faced regulatory challenges, including a notice from the China Securities Regulatory Commission regarding information disclosure violations, which may impact investor confidence[3]. - The company is closely monitoring regulatory changes in the pharmaceutical sector to ensure compliance and adapt to new market conditions[28]. - The company has implemented measures to ensure compliance with market regulations and prevent price manipulation in the raw material market[65]. - The company has been under investigation by the China Securities Regulatory Commission since December 2023 for suspected violations of information disclosure laws[104]. Environmental and Sustainability Efforts - The company has implemented a third-party environmental monitoring scheme, focusing on wastewater and air emissions, to ensure compliance with environmental standards[78]. - The company has established a pollution emergency response plan, which was revised in February 2023 and filed with the local environmental bureau[77]. - The company has committed to measures to reduce carbon emissions, although specific effects were not disclosed[94]. - The company has established criteria for recognizing discontinued operations, which include components that represent a major business or geographical area that has been disposed of or classified as held for sale[196]. Legal Matters - The company is involved in a lawsuit regarding performance commitment compensation against Dongsheng Group, with the case registered at the Xi'an Intermediate People's Court as of June 20, 2024[99]. - The company has been actively pursuing legal actions to recover debts from various parties, including a claim of 190,562.67 yuan against Shanghai Ciji Pharmaceutical Co., Ltd.[102]. - The company received a fine of 8 million yuan from the Shanxi Securities Regulatory Bureau for information disclosure violations[104]. - The company has not fulfilled court judgments totaling RMB 7.8262 million and RMB 215,800 related to contract disputes[106]. Corporate Governance - The company has committed to improving its corporate governance structure and comply with regulations regarding related transactions[97]. - The company has established an independent financial department and accounting system to ensure compliance with relevant laws and regulations[96]. - The company held its annual general meeting on June 28, 2024, where several key reports and proposals were approved, including the three-year shareholder return plan[67]. - The company experienced changes in its board of directors, with the election of Wang Jijun as an independent director following the resignation of several key executives[68]. Shareholder Information - As of the report date, the total number of ordinary shareholders was 67,350, with the largest shareholder, Jinchuang Investment Co., Ltd., holding 71,508,968 shares, representing 14.61% of the total shares[115]. - The top three shareholders include Jinchuang Investment Co., Ltd. (14.61%), Jiang Shibo (1.67%), and Xi'an Dongsheng Group Co., Ltd. (0.90%) as of the report date[115]. - The company has not reported any changes in share capital structure during the reporting period[114]. - The company has not disclosed any significant asset acquisitions or sales during the reporting period[109].